Evaluate Vantage Homepage
Cytokine players keep the faith
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
The Sting is dead; long live the Sting
Yesterday’s deal between GSK and Mersana threw the spotlight back on a forgotten oncology mechanism.
Pfizer bets $5.4bn against gene therapies in sickle cell
Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.
Medtech
Trad device start-ups catch the cash
Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.
Delfi aims for a cheaper liquid biopsy
With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.
Company Events
Go or no go? J&J’s bispecific FDA first
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
Go or no go? FDA firsts for Imfinzi, Enhertu and roflumilast
Assets in oncology and psoriasis are set for upcoming Pdufa decisions.
Key data catalysts for the industry’s small players
Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.
Interviews
Delfi aims for a cheaper liquid biopsy
With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.
Cytokinetics aims to become the Vertex of cardiovascular disease
But a surprise adcom for omecamtiv mecarbil might put a spanner in the works.
To back, or back away from, digital health?
Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.